Hovdenes J, Solheim B G
Røde Kors og Rikshospitalets Blodsenter, Oslo.
Tidsskr Nor Laegeforen. 1995 May 10;115(12):1499-501.
For 30 years it has been known that immunodeficient patients can have a fatal reaction to transfused blood components containing viable lymphocytes. This risk of a transfusion-associated graft-versus-host reaction can be totally eliminated by irradiation of the blood prior to transfusion. Immunocompetent individuals can have this potentially fatal reaction if the blood donor is homozygous for one of the HLA-haplotypes of the recipient. The probability of this coincidence is low when donor and recipient are unrelated, but considerably higher when they are genetically related. When HLA-matched blood platelets are indicated for transfusing patients refractory to random platelets, the platelets must always be irradiated with minimum 25 Gy, since a large proportion of the donors will be homozygous with one of the HLA-haplotypes of the recipient.
30年来，人们一直知道免疫缺陷患者可能会对含有存活淋巴细胞的输血成分产生致命反应。输血相关移植物抗宿主反应的这种风险可以通过在输血前对血液进行辐照而完全消除。如果献血者与受者的一种HLA单倍型纯合，免疫功能正常的个体也可能发生这种潜在的致命反应。当供者和受者无血缘关系时，这种巧合的概率很低，但当他们有遗传关系时，概率会高得多。当需要为对随机血小板无效的患者输注HLA匹配的血小板时，血小板必须始终用至少25 Gy的剂量进行辐照，因为很大一部分供者将与受者的一种HLA单倍型纯合。
